HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD: Insufficient Evidence To Equate Olay Pro-X Device With Clarisonic

This article was originally published in The Rose Sheet

Executive Summary

National Advertising Division recommends that P&G refrain from making claims of comparable effectiveness between its Olay Pro-X Advanced Cleansing System and L’Oreal’s Clarisonic Skin Cleansing System without adequate test data to support such statements.

You may also be interested in...



Clarisonic Energizes L’Oreal Luxe Sales As Firm Eyes Global Rollout

“A kind of miracle,” according to L’Oreal CEO Jean-Paul Agon, Clarisonic grew 61% in the firm’s third quarter, and the brand’s “globalization” is still to come. Lancome also helped to boost sales in the firm’s Luxe division 6.6%, on a like-for-like basis, to roughly €1.4 billion ($1.79 billion) for the quarter.

China Regulatory Probe Slows Nu Skin Growth After Record Year

The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.

China Regulatory Probe Slows Nu Skin Growth After Record Year

The firm’s recent explosive growth is expected to slow substantially in the first quarter – to between 20% and 24% – but Nu Skin is confident the steps it is taking in China “make our long-term success more likely.” Analysts have faith in the firm as it works with Chinese officials to resolve an investigation into its business practices.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel